MannKind reported $76.53M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
Adma Biologics USD 121.98M 4.43M Jun/2025
Dynavax Technologies USD 95.44M 30.44M Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Halozyme Therapeutics USD 206M 59M Jun/2025
Insmed USD 107.4M 14.58M Jun/2025
MacroGenics USD 22.24M 2.89M Jun/2025
MannKind USD 76.53M 1.82M Jun/2025
Merck USD 15.81B 280M Jun/2025
Novo Nordisk DKK 154.94B 76.85B Jun/2025
Pfizer USD 14.7B 980M Jun/2025
Sanofi EUR 9.99B 90M Jun/2025
Xencor USD 43.61M 10.88M Jun/2025